TG Therapeutics (TGTX) Proceeds From Repayments Of Secured Debt — Quarterly & Annual

Screener

Proceeds From Repayments Of Secured Debt at other companies

Parke BancorpPKBK

$24M+580%

Papa John's InternationalPZZA

$0—

TG TherapeuticsTGTX

-$255M—

KemperKMPR

$0-100%

Bar Harbor BanksharesBHB

$0+100%

Summit Hotel PropertiesINN

-$11.36M—

Other financials

Income statement

Revenue$240.3M+70.3%

Gross profit$199.1M+62.9%

Operating income$21.7M-37.8%

Net income$7.8M-72.4%

EPS (diluted)$0.05-70.6%

Balance sheet

Cash & equivalents$482.6M+274%

Total debt$754.4M+197%

Total equity$604.1M+119%

Total assets$1.6B+133%

Cash flow

Operating cash flow$39.3M—

CapEx$293.0K+598%

Free cash flow$39.0M—

Valuation

Market cap$7.58B+72.5%

Enterprise value$7.86B+73.7%

P/E17.2×-55.6×

P/S9.5×-0.2×

Profitability

Gross margin82.4%-4.6pp

Operating margin17.1%-1.9pp

Net margin55.2%+41.9pp

FCF margin-6,328.4%+4,773pp

Returns & leverage

Return on equity100.3%+73.6pp

Debt / equity1.2×+0.3×

Current ratio4.3×+0.4×

Where this comes from

Reported directly by TG Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromRepaymentsOfSecuredDebt.

The source filing: TG Therapeutics’s 10-Q, filed May 6, 2026. Open the filing →

Filed: May 6, 2026, 5:00 PM EDT
Fiscal quarter: Q1 FY2026
Calendar quarter: Q1 2026
Accession: 0001437749-26-015246

FAQ

What is TG Therapeutics's proceeds from repayments of secured debt?: TG Therapeutics (TGTX) reported proceeds from repayments of secured debt of -$255M in Q1 2026.
What does proceeds from repayments of secured debt mean?: Proceeds From Repayments Of Secured Debt as reported by TG Therapeutics, Inc..

Ask your AI about TG Therapeutics's proceeds from repayments of secured debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk